PFE PFIZER INC
Price Chart
Executive Summary
CICC initiates Pfizer (PFE) at Outperform with a $33 price target, implying 15.6% upside from the current $28.55. The move contrasts with a divided analyst base: 26 analysts show a mean PT of $28.58 and median of $27, with 37% Buy, 31% Hold, and 32% Sell ratings. CICC’s accuracy is 55% (17/31 calls correct), below top-tier firms like Morgan Stanley (71%, 5/7) and Cantor (59%, 10/17). Recent analyst activity includes one upgrade and no downgrades in 30 days. EPS estimates are trending down: -8bps in +1q EPS over 30 days. Institutional flows are mixed — Renaissance Technologies exited while Two Sigma increased position 27x. No insider trades or short interest data available. Earnings date not disclosed.
Impact Score
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-04-16 | CICC | initiate | Outperform | $33.00 |
| 2026-04-13 | UBS | maintain | Neutral | $27.00 |
| 2026-04-10 | Morgan Stanley | maintain | Equal-Weight | $28.00 |
| 2026-04-09 | B of A Securities | maintain | Neutral | $26.00 |
| 2026-03-24 | Guggenheim | maintain | Buy | — |
| 2026-03-17 | HSBC | maintain | Buy | — |
| 2026-03-02 | Argus Research | upgrade | Buy | — |
| 2026-02-25 | RBC Capital | initiate | Underperform | $25.00 |
| 2026-02-20 | Barclays | initiate | Underweight | $25.00 |
| 2026-02-09 | Freedom Broker | maintain | Buy | — |
Over the past 30 days, there has been 1 upgrade (Argus Research) and 0 downgrades. EPS revisions are negative: +1q EPS estimate down 8 cents over 30 days (from $0.7096 to $0.7017), +1y down 8 cents (from $2.831 to $2.823), indicating weakening sentiment despite isolated bullish calls.
Firm Track Record — CICC
CICC accuracy: 55% on 31 calls | avg return: 1.4%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 7 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Morgan Stanley | 71% | 5/7 | 4.2% | top tier |
| B of A Securities | 67% | 2/3 | -0.1% | top tier |
| Cantor Fitzgerald | 59% | 10/17 | 1.8% | above average |
| Citigroup | 50% | 1/2 | -5% | below average |
| Barclays | 50% | 1/2 | -1.2% | below average |
| Guggenheim | 40% | 2/5 | -1.4% | below average |
| UBS | 40% | 2/5 | -2.7% | below average |
CICC has a 55% accuracy rate (17/31 calls correct), below Morgan Stanley (71%, 5/7) and B of A Securities (67%, 2/3), but above Guggenheim (40%, 2/5) and UBS (40%, 2/5). Its average return of +1.4% ranks in the middle tier. Top-performing firm is Morgan Stanley with +4.2% avg return.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| +1q | $0.70 | $0.61 — $0.91 | $14.5B | ↑0 ↓0 |
| +1y | $2.82 | $2.48 — $3.03 | $58.9B | ↑1 ↓0 |
| 0y | $2.96 | $2.80 — $3.17 | $61.2B | ↑1 ↓0 |
| 0q | $0.73 | $0.64 — $0.92 | $13.9B | ↑1 ↓0 |
Cross-Platform Signals
Institutional activity is mixed: Two Sigma increased its stake by 2734.9%, while Renaissance Technologies fully exited a $1.8B position. Norges Bank both entered and later exited — suggesting volatility. No insider trades reported. Congressional buys: Susan Collins (R) bought $15K–$50K on Feb 3; Gilbert Cisneros (D) bought $1K–$15K on Feb 10. Signal divergence: analyst initiation is bullish, but institutional and EPS trends are neutral-to-weak.
Actionable Insight
CICC’s initiation is a contrarian bullish signal from a mid-tier firm, but lacks confirmation from EPS revisions or institutional momentum. Monitor for follow-up upgrades or Q1 earnings catalysts before positioning.
Documents Analyzed
Report based on filing metadata.
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 16, 2026
24d ago
|
ANALYST-UPGRADE
| $27.20 $25.75 | ▼ −5.34% | ▼ −11.98% | $25.62 (−5.80%) |
|
May 16, 2026
24d ago
|
ANALYST-UPGRADE
| $27.24 $27.76 | ▲ +1.91% | ▲ +9.84% | $25.62 (−5.94%) |
|
May 5, 2026
5w ago
|
8-K
| $26.43 $25.55 | ▼ −3.31% | ▼ −8.27% | $25.62 (−3.05%) |
|
Apr 16, 2026
7w ago
|
ANALYST-UPGRADE
| $27.20 $25.96 | ▼ −4.55% | ▼ −10.36% | $25.62 (−5.80%) |
|
Apr 16, 2026
7w ago
|
ANALYST-UPGRADE
| $27.20 $25.96 | ▼ −4.55% | ▼ −10.36% | $25.62 (−5.80%) |
|
Mar 12, 2026
12w ago
|
DEFA14A
| $26.86 $26.90 | ▲ +0.15% | ▼ −1.83% | $25.62 (−4.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access